The ANCA Renal Risk Score (ARRS) — based on kidney biopsy and lab results — could accurately predict kidney failure in a large group of Scottish people with ANCA-associated vasculitis (AAV), a study shows. The test better discriminates the risk of kidney failure in AAV and may offer clinicians…
Two years of treatment with Nucala (mepolizumab) safely and effectively reduces signs and symptoms of hard-to-treat eosinophilic granulomatosis with polyangiitis (EGPA), the rarest form of ANCA-associated vasculitis. That’s according to a real-world study in Italy that also found similar outcomes with benralizumab, a therapy that works similarly to…
Urine levels of scarring, inflammation, and kidney damage biomarkers accurately reflect kidney biopsy results and predict kidney outcomes in people with ANCA-associated vasculitis (AAV), a pilot study suggests. According to its researchers, noninvasive urine tests could be used to monitor tissue or functional changes in the kidneys. Also, urinary…
The incidence of ANCA-associated vasculitis (AAV) in southern Sweden was stable over a 23-year period, while its prevalence, the total number of cases overall, increased, a study showed. Stable incidence, or the same number of new cases per year, with a higher prevalence “might indicate better management and treatment…
A specific variant in both copies of the gene that codes for proteinase 3 (PR3) — one of the most common targets of ANCA-associated vasculitis (AAV)-driving antibodies — is linked to a nearly five times higher risk of severe relapse in people with PR3-associated AAV, a study found. While…
The European Alliance of Associations for Rheumatology (EULAR) has updated its recommendations on managing ANCA-associated vasculitis (AAV) based on new research and clinical data. Four overarching principles were introduced — the importance of patient-physician joint decisions, disease education, routine screening for treatment side effects and additional medical conditions,…
Concerns about the future, their disease’s social and emotional impact, and bodywide symptoms were prominent among those reported by ANCA-associated vasculitis (AAV) patients with low disease activity in a survey study from Mexico. People were responding to the AAV patient-reported outcomes (AAV-PRO) questionnaire, and its specific domains were found to associate…
Tavneos (avacopan) effectively reverses severe kidney disease associated with ANCA-associated vasculitis (AAV) compared with standard steroid therapy, according to a subgroup analysis of the Phase 3 ADVOCATE clinical trial. Greater improvements in kidney function with Tavneos were sustained for the two months of follow-up after the treatment stopped.
Patients with ANCA-associated vasculitis (AAV) have a higher risk of mortality than the general population, especially those who are older or have impaired kidney function, a long-term outcome analysis study has found. Infections were the leading cause of death, with treatment complications, such as immunosuppression and blood vessel inflammation,…
The CoronaVac COVID-19 vaccine has an excellent safety profile, but generates only a moderate immune response in people with ANCA-associated vasculitis (AAV), a clinical trial analysis found. Although the levels of vaccine-induced antibodies against SARS-CoV-2, the virus that causes COVID-19, declined over six months, a booster shot was shown…
Get regular updates to your inbox.